Genetesis Announces Formal Publication of Results from the MAGNETO Trial
Results highlight resting MCG as a rapid, radiation-free alternative to standard of care stress testing for diagnosing myocardial ischemia in acute chest pain patients
MASON, Ohio, April 02, 2024–(BUSINESS WIRE)–Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that official results from its MAGNETO trial were published in a special issue of the American Heart Journal Plus: Cardiology Research and Practice. The results of MAGNETO demonstrate MCG’s ability to identify myocardial ischemia in low-to-intermediate risk patients presenting to the emergency department (ED) with acute chest pain and validate MCG’s performance compared to tests that comprise the current standard of care. These traditional forms of testing are currently guideline recommended despite their limited efficacy, lengthy duration, high cost, and exposure of patients to additional risk (e.g., radiation).
